A biopharmaceutical company focused on the development of its
proprietary “Apofusion” technology. This innovative technology is the
first to combine two pivotal, naturally occurring, cellular mechanisms
in a single human fusion protein. These “apofusions” are composed
of a cell suicide inducing protein fused on the DNA level to a targeting
protein. The New Biological Entities specifically target diseased
cell populations and selectively eliminate them. The use of human
apoptosis-inducing proteins results in elimination of target cells
without evoking side effects or immune responses, thus enabling a
wide therapeutic range.
Based on its proprietary technology, the company has developed 4
products achieving proof-of-concept in animal studies, all showing
specific cell elimination with no apparent toxicity. The company
has shown successful treatment of solid tumors, autoimmune
diseases, allergic reactions and neurological diseases. Target-In’s
lead compound has shown beneficial effects against various animal
variations of disease such as Diabetes, inflammatory bowel disease
and bone-marrow transplantation. First human trials in Lymphoma
patients are anticipated in 2009.
Based on its broad technology platform and robust pipeline of
products, the company intends to develop selected products to the
level of human proof of efficacy in-house, while out-licensing other
products to strategic partners. Two such deals have already been
signed, and discussions are undergoing with additional companies.
Six families of patents have been filed, most of them already issued.
The company is lead by a highly experienced international team. R&D
is managed in an from the Israeli office while business development is
managed from the US office.